Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
The Association of Mir-Let 7B and Mir-548 With Pten in Prostate Cancer Pubmed



Saffari M1, 2 ; Ghaderian SMH3 ; Omrani MD4 ; Afsharpad M5 ; Shankaie K6 ; Samadaian N7
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Medical Genetics, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  2. 2. Cancer Biology Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Chronic Kidney Disease Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  4. 4. Urogenital Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  5. 5. Cancer Control Research Center, Cancer Control Fundation, Iran University of Medical Sciences, Tehran, Iran
  6. 6. Department of Biology, Science and research branch, Islamic Azad University, Tehran, Iran
  7. 7. Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

Source: Urology Journal Published:2019


Abstract

Purpose: This study aims to investigate the expression level of mir-let7b-3p and mir-548, which are involved in PTEN expression in tissue samples of prostate cancer patients versus benign prostate hyperplasia (BPH) and normal adjacent tissue. Materials and Methods: Prostate cancer tissues were obtained from patients after receiving informed consent. Total RNA extraction and cDNA synthesis were performed for determining gene expression. Results: Ten patients were determined to have high Gleason scores (> 7), 36 and seven samples had intermediate Gleason scores (7≥) and BPH, respectively, and 40 samples were derived from normal adjacent tissue. Downregulation of mir-let7b and upregulation of mir-548 expression significantly correlated with high-risk Gleason scores. Conclusion: The present study showed that miR-let7b and/or mir-548 can be considered as potential targets in prostate cancer therapy. © 2018 Urology and Nephrology Research Centre.